RT Journal Article SR Electronic T1 Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2 JF bioRxiv FD Cold Spring Harbor Laboratory SP 2020.12.23.424232 DO 10.1101/2020.12.23.424232 A1 Laura N Jeffreys A1 Shaun H Pennington A1 Jack Duggan A1 Claire H Caygill A1 Rose C Lopeman A1 Alastair F Breen A1 Jessica B Jinks A1 Alison Ardrey A1 Samantha Donnellan A1 Edward I Patterson A1 Grant L Hughes A1 David W Hong A1 Paul M O’Neill A1 Ghaith Aljayyoussi A1 Andrew Owen A1 Stephen A Ward A1 Giancarlo A Biagini YR 2021 UL http://biorxiv.org/content/early/2021/09/01/2020.12.23.424232.abstract AB A key element for the prevention and management of COVID-19 is the development of effective therapeutics. Drug combination strategies of repurposed drugs offer several advantages over monotherapies, including the potential to achieve greater efficacy, the potential to increase the therapeutic index of drugs and the potential to reduce the emergence of drug resistance. Here, we report on the in vitro synergistic interaction between two FDA approved drugs, remdesivir and ivermectin resulting in enhanced antiviral activity against SARS-CoV-2. These findings warrant further investigations into the clinical potential of this combination, together with studies to define the underlying mechanism.Competing Interest StatementA.O. is a Director of Tandem Nano Ltd. A.O. has received research funding from ViiV, Merck, Janssen and consultancy from Gilead. These associations had no influence over the content of the current manuscript. P.O.N. is currently engaged in a collaboration with Romark LLC but this interaction had no influence over the content of the current manuscript. No other conflicts are declared by the authors.